EUVIMEDEUVIMED entdecken
Crossref

Nerandomilast (Jascayd) for Idiopathic Pulmonary Fibrosis

The Medical Letter on Drugs and Therapeutics · 22.12.2025 · 67 (1744) · 207-207

DOI: 10.58347/tml.2025.1744d ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.12.2025. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nerandomilast (Jascayd – Boehringer Ingelheim), an oral phosphodiesterase 4 (PDE4) inhibitor, has been approved by the FDA for treatment of idiopathic pulmonary fibrosis (IPF) in adults. It is the third drug to be approved in the US for this indication; the oral antifibrotic drugs pirfenidone (Esbriet, and generics) and nintedanib (Ofev) were approved in 2014.

Schlagwörter

Stichwörter der Autor:innen

EsbrietJascaydOfevadverse effectsdosagedrug interactionsefficacyidiopathic pulmonary fibrosisnerandomilastnintedanibpirfenidonesafety

Zitieren

APA

(2025). Nerandomilast (Jascayd) for Idiopathic Pulmonary Fibrosis. The Medical Letter on Drugs and Therapeutics, 67(1744), 207-207. https://doi.org/10.58347/tml.2025.1744d

Vancouver

Nerandomilast (Jascayd) for Idiopathic Pulmonary Fibrosis. The Medical Letter on Drugs and Therapeutics. 2025;67(1744):207-207. doi:10.58347/tml.2025.1744d

BibTeX
@article{euvimed2025,
  title = {Nerandomilast (Jascayd) for Idiopathic Pulmonary Fibrosis},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2025},
  volume = {67},
  number = {1744},
  pages = {207--207},
  doi = {10.58347/tml.2025.1744d}
}
Kostenlos starten →